FGFR-Portal

Quality in Pathology GmbH (QuIP) was established with the aim of providing support services to pathologists in Germany and Europe, optimizing their testing results, and offering assistance for all of the relevant scientific and organizational activities required for quality assurance work. The FGFR-Portal was set up to offer pathologists, consultants working in other disciplines, and oncologists orientation at the interface between biomarker tests and therapy options. The Portal hosts a biomarker-based therapy algorithm. This algorithm is based both on current medical guideline recommendations as well as the latest scientific findings, and provides full details of the underlying investigations.

Background

FGFR pathway alterations have been implicated in approximately 7 % of cancer entities. Due to the proliferative behavior of FGFR alterations in cancer, FGFR inhibitors have emerged as potential targeted therapeutic agents in recent years. The promising results of FGFR inhibitors in advanced unresectable cholangiocarcinoma harboring FGFR2 fusions and in metastatic urothelial carcinoma with FGFR2 and FGFR3 genetic alterations led to their accelerated approval in cholangiocarcinoma and urothelial carcinoma.

While specific biomarker-tested therapies for advanced altered urothelial and cholangiocarcinoma have been approved, additional studies are being conducted on various tumor entities which could expand the use of this specific inhibitor for different types of cancers. The portal will provide comprehensive information on different FGFR alterations and their detection, serving as an interdisciplinary resource for diagnostics, molecular pathology and biomarker determination for a wide range of tumor entities. It includes algorithms that offer detailed information on tests, corresponding results and different therapy options. In parallel, users will be able to access the portal via specific tumor entities or via approved drugs.The content of the FGFR portal is developed in collaboration with and reviewed by recognized experts in the field.

References and citations on the Portal

The underlying sources from the research literature consulted by the portal content authors are cited as a list on a separate “References” tab on each of the relevant algorithm pages. In each case, these research references and citations reflect the current state of progress on the part of the scientific experts, and will be updated/amended regularly by the team as necessary.

Disclaimer

Please note: The information provided on our FGFR-Portal is shared to the best of our knowledge. However, we cannot guarantee the completeness, accuracy, or timeliness of the content. This is especially true for content that originates from third parties and is merely linked on our website. For the most current and detailed information on the medications, the respective technical information should be consulted.

Data protection regulations in Germany mean that the portal and the link to the portal may not be shared publicly. After an initial overview about the portal's homepage, the full site with all its content is only available to healthcare professionals.

Registered QuIP customers will find links to the various portals on the central QuIP page after logging in. All medical professionals who have DocCheck access also have access. All other interested parties without a QuIP account or DocCheck access can access the portals with a QuIP activation code after sending an e-mail to QuIP and briefly checking their access requirements.

Quality in Pathology GmbH

The FGFR portal is supported by Incyte, Janssen-Cilag and Taiho Oncology Europe